![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » GSK WITHDRAWS INDIAN PATENT APPLICATION FOR COMBIVIR
GSK WITHDRAWS INDIAN PATENT APPLICATION FOR COMBIVIR
August 21, 2006
UK-based drugmaker GlaxoSmithKline (GSK) has withdrawn its patent application in India for its HIV drug Combivir.
The company denied it withdrew the application under pressure from activists, who had protested at an Indian patent office.
The company had filed for a patent for Combivir, which is a combination of Epivir and Retrovir, nearly eight years ago. However, the Indian Network for People Living with HIV/AIDS and the Manipur Network of Positive People filed a pre-grant opposition stating the drug was not a new invention.
Combivir is a widely used fixed-dose
combination and is a preferred drug of many international organizations.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct